The Cellular Therapies Working Party wants to hear from you! 🫵
Human platelet lysate (HPL) has been a central topic in the ISBT Working Party for Cellular Therapies for years. In 2020, the working party published a statement on the standardization of HPL production and quality requirements.
The objective of the below survey is to obtain information from blood establishments worldwide on the use of platelet concentrates for the production of HPL to supplement growth media for human cell propagation in order to determine the status, conditions, standardization efforts and potential difficulties.
